Diabetes Channel
Topics
Medications
Quicklinks
Related Channels

Precautions and Warnings With Sitagliptin/Simvastatin

Specific Sitagliptin/Simvastatin Precautions and Warnings

Some warnings and precautions to be aware of prior to taking this medication include the following:
 
  • Very preliminary data suggests incretin mimetics, such as sitagliptin/simvastatin, may increase the risk of precancerous cellular changes (called pancreatic duct metaplasia) in people with type 2 diabetes. Researchers are continuing to study the possibility that incretin mimetics might increase the risk of pancreatic cancer, although at this time there is not enough information to know for sure if there is any increased risk.
 
  • There have been some reports of pancreatitis in people taking sitagliptin (one of the active ingredients in sitagliptin/simvastatin). This is probably most likely to occur shortly after the drug is first started or when the dosage is increased. Make sure to let your healthcare provider know right away if you have signs of pancreatitis, such as:
 
    • Nausea
    • Vomiting
    • Loss of appetite
    • Severe, persistent abdominal (stomach) pain that sometimes radiates to the back.
 
  • Rhabdomyolysis (the severe breakdown of muscles) and other serious muscle problems have rarely been reported with statins, including simvastatin (one of the active ingredients in sitagliptin/simvastatin). You have an increased risk for developing muscle problems with sitagliptin/simvastatin if you:
 
 
  • Make sure to contact your healthcare provider immediately if you experience any muscle pain, weakness, or tenderness, especially if you also have a fever or feel ill (see Juvisync and Muscle Pain).
 
  • If you are an alcoholic or drink alcohol frequently, discuss this with your healthcare provider prior to starting sitagliptin/simvastatin.
 
  • Statins, including simvastatin (one of the components of sitagliptin/simvastatin), have been known to cause an increase in liver enzymes. Therefore, it is recommended that you have a blood test that looks at your liver function before starting sitagliptin/simvastatin and periodically thereafter. These tests may also be recommended if the sitagliptin/simvastatin dosage is changed (see Juvisync and Liver Damage).
 
  • This drug is not appropriate for people with moderate-to-severe kidney impairment. Your kidney function should be checked with a blood test before you start this medication.
 
  • Sitagliptin/simvastatin is a pregnancy Category X medicine, meaning that it could potentially cause harm to your unborn child. The safety of sitagliptin/simvastatin in pregnant women has not been established. If you are pregnant and taking sitagliptin/simvastatin, talk to your healthcare provider immediately (see Juvisync and Pregnancy).
 
  • It is unknown whether sitagliptin/simvastatin passes through breast milk. Therefore, if you are breastfeeding or plan to start, discuss this with your healthcare provider prior to taking the drug (see Juvisync and Breastfeeding).
 
Steps to Prevent or Delay Diabetic Nerve Damage

Sitagliptin/Simvastatin Drug Information

Terms of Use
Advertise with Us
Contact Us
About eMedTV
Privacy Policy
Copyright © 2006-2017 Clinaero, Inc.
eMedTV serves only as an informational resource. This site does not dispense medical advice or advice of any kind. Site users seeking medical advice about their specific situation should consult with their own physician. Click Terms of Use for more information.